A Bioequivalence Bridging Study for Cotempla XR-ODT (Methylphenidate Extended-Release Orally Disintegrating Tablet)

Trial Profile

A Bioequivalence Bridging Study for Cotempla XR-ODT (Methylphenidate Extended-Release Orally Disintegrating Tablet)

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Aug 2016

At a glance

  • Drugs Methylphenidate (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 18 Aug 2016 New trial record
    • 28 Jul 2016 According to a Neos Therapeutics media release, the company will re-submit the New Drug Application to the FDA for Cotempla XR-ODT by the end of this year and the anticipated marketing approval in time for the 2017.
    • 28 Jul 2016 According to a Neos Therapeutics media release, on November 6, 2015, the company has received a complete response letter by the U.S. Food and Drug Administration (FDA) requiring the company to conduct a bridging study to demonstrate bioequivalence between the clinical trial material and the to-be-marketed commercial scale drug product, including an assessment of food effect, and to provide validation and three months of stability data.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top